Sirona Biochem (Seite 530)
eröffnet am 23.06.13 12:55:10 von
neuester Beitrag 08.05.24 17:10:08 von
neuester Beitrag 08.05.24 17:10:08 von
Beiträge: 31.047
ID: 1.183.167
ID: 1.183.167
Aufrufe heute: 36
Gesamt: 5.405.217
Gesamt: 5.405.217
Aktive User: 0
ISIN: CA82967M1005 · WKN: A0RM6R · Symbol: ZSB
0,0435
EUR
-3,33 %
-0,0015 EUR
Letzter Kurs 17.05.24 Tradegate
Neuigkeiten
07.05.24 · IRW Press |
07.05.24 · globenewswire  |
08.04.24 · globenewswire |
05.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +46,48 | |
| 2,3300 | +42,07 | |
| 1,1400 | +30,85 | |
| 2,7700 | +25,91 | |
| 2,4200 | +16,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,1000 | -15,76 | |
| 2,3100 | -16,61 | |
| 0,9100 | -17,27 | |
| 4,2300 | -18,65 | |
| 5,0000 | -37,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Stellt euch vor die Trendlinie würde im Wert sinken, dann wärs ja fürchterlich. 
Hrubesch, mit Sirona reich zu werden ist ein bisschen so wie mit Botox schön zu werden....
Sind wir jetzt Reich??? Prosit...
Antwort auf Beitrag Nr.: 68.804.909 von E301173K am 17.07.21 12:49:18... um so eher könnte der Fluoriniserungs-Prozess evtl. eine Chance haben.
Das muss ausprobiert werden.
Sollte es da einen Deal Sirona mit einem Pharma-Riesen geben, wäre das sehr interessant.
Das muss ausprobiert werden.
Sollte es da einen Deal Sirona mit einem Pharma-Riesen geben, wäre das sehr interessant.
Antwort auf Beitrag Nr.: 68.804.828 von Geheimnisvoller am 17.07.21 12:34:25Das isz auch noch gut zu wissen;
https://www.finanzen.net/nachricht/aktien/keine-wirksamkeit-…
https://www.finanzen.net/nachricht/aktien/keine-wirksamkeit-…
Trading Spotlight
Antwort auf Beitrag Nr.: 68.804.846 von Geheimnisvoller am 17.07.21 12:35:57Ich glaube ich muss mal einen Englischkurs machen :-)
- Sirona's synthetic chemists have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule....
https://www.sironabiochem.com/programs/proprietary-platform-…
My conclusion:
Such carbohydrate molecules are used by various viral agents to bond to the cells. If this is no longer possible, the virus cannot use the replication mechanism of the cells.
https://www.sironabiochem.com/programs/proprietary-platform-…
My conclusion:
Such carbohydrate molecules are used by various viral agents to bond to the cells. If this is no longer possible, the virus cannot use the replication mechanism of the cells.
Antiviraler Tweet - Chance for Sirona
https://twitter.com/i/topics/news/e638521389?
cn=ZmxleGlibGVfcmVjcw%3D%3D&refsrc=https://www.scientificamerican.com/article/there-are-few-goo…
This could be a very big chance fr Sirona Biochem ...
-Two of the current best available treatments, monoclonal antibodies and the drug remdesivir, are given by infusion. Patients only benefit during the first week or so of infection, when the virus is still present and replicating in the body. These medications are expensive and often unavailable outside of large teaching hospitals. In many instances, patients are treated too late, after the disease has already shifted to a more dangerous hyperinflammatory state.
-Biden administration announced in June that it would spend more than $3 billion on a program aimed at developing next-generation antiviral therapies—not just for COVID but also for other viruses that pose a future threat.
- The goal of an antiviral pill is to stop the pathogen from replicating, but finding drugs that can do that without injuring the infected human cell is no easy task. Scientists start by screening thousands of compounds for their efficacy in targeting SARS-CoV-2 in cell culture. Promising candidates are then tested in animals—both to ensure that the drugs are not toxic and that they are not immediately destroyed in the body and reach tissues in the lungs and other organs in sufficient amounts.
-Rachel Bender Ignacio, a physician-scientist at the Fred Hutchinson Cancer Research Center in Seattle, anticipates that the virus will develop less resistance against direct-acting small-molecule drugs such as molnupiravir than it has against monoclonal antibodies.
-Molnupiravir, which is in a class of drugs called nucleoside analogues, works by inserting itself into a newly forming viral RNA strand. The strand will then stop growing or become so heavily mutated that replication cannot continue. Scientists say molnupiravir and other direct-acting agents can also be combined in therapeutic cocktails, mirroring how drugs for viral diseases such as HIV and hepatitis C are given today. “You’re looking for drugs with different and complimentary mechanisms of action,” Sheahan says.
- Sirona's synthetic chemists have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule....
Such carbohydrate molecules are used by various viral agents to bond to the cells. If this is no longer possible, the virus cannot use the replication mechanism of the cells.
https://twitter.com/i/topics/news/e638521389?
cn=ZmxleGlibGVfcmVjcw%3D%3D&refsrc=https://www.scientificamerican.com/article/there-are-few-goo…
This could be a very big chance fr Sirona Biochem ...
-Two of the current best available treatments, monoclonal antibodies and the drug remdesivir, are given by infusion. Patients only benefit during the first week or so of infection, when the virus is still present and replicating in the body. These medications are expensive and often unavailable outside of large teaching hospitals. In many instances, patients are treated too late, after the disease has already shifted to a more dangerous hyperinflammatory state.
-Biden administration announced in June that it would spend more than $3 billion on a program aimed at developing next-generation antiviral therapies—not just for COVID but also for other viruses that pose a future threat.
- The goal of an antiviral pill is to stop the pathogen from replicating, but finding drugs that can do that without injuring the infected human cell is no easy task. Scientists start by screening thousands of compounds for their efficacy in targeting SARS-CoV-2 in cell culture. Promising candidates are then tested in animals—both to ensure that the drugs are not toxic and that they are not immediately destroyed in the body and reach tissues in the lungs and other organs in sufficient amounts.
-Rachel Bender Ignacio, a physician-scientist at the Fred Hutchinson Cancer Research Center in Seattle, anticipates that the virus will develop less resistance against direct-acting small-molecule drugs such as molnupiravir than it has against monoclonal antibodies.
-Molnupiravir, which is in a class of drugs called nucleoside analogues, works by inserting itself into a newly forming viral RNA strand. The strand will then stop growing or become so heavily mutated that replication cannot continue. Scientists say molnupiravir and other direct-acting agents can also be combined in therapeutic cocktails, mirroring how drugs for viral diseases such as HIV and hepatitis C are given today. “You’re looking for drugs with different and complimentary mechanisms of action,” Sheahan says.
- Sirona's synthetic chemists have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule....
Such carbohydrate molecules are used by various viral agents to bond to the cells. If this is no longer possible, the virus cannot use the replication mechanism of the cells.
Antwort auf Beitrag Nr.: 68.801.612 von Cryptohans am 16.07.21 19:58:41Schon mal die Idee verfolgt, dass die Tweets gar nicht an Anleger adressiert sind? Und dass die, an die sie gerichtet sind, auch sicher nicht die sind, die so kleinkindisch darauf reagieren?
https://twitter.com/i/topics/news/e638521389?cn=ZmxleGlibGVf…
https://www.scientificamerican.com/article/there-are-few-goo…
Hier liegt eine große Chance für Sirona Biochem:
- antivirales Medikament, welches Replikation erschwert durch Fluorinisierung
- Aufnahme in den erlesenen Kreis auserwählter Moleküle
- Somit finanzielle Unterstützung durch Regierungen
- Wäre komplette Neubewertung für die Zukunft
https://www.scientificamerican.com/article/there-are-few-goo…
Hier liegt eine große Chance für Sirona Biochem:
- antivirales Medikament, welches Replikation erschwert durch Fluorinisierung
- Aufnahme in den erlesenen Kreis auserwählter Moleküle
- Somit finanzielle Unterstützung durch Regierungen
- Wäre komplette Neubewertung für die Zukunft
Durchsuchen
Sirona Biochem
